What is the primary use of Integrilin (eptifibatide)?

Integrilin (eptifibatide) is primarily used in the management of acute coronary syndrome (ACS) and during percutaneous coronary intervention (PCI). It is a glycoprotein IIb/IIIa inhibitor that works by preventing platelets from aggregating and forming clots, which is critical during episodes of ACS where there is a risk of myocardial infarction due to unstable plaque in the coronary arteries. By inhibiting platelet aggregation, Integrilin helps to minimize the risk of serious complications during procedures like PCI, where the aim is to restore blood flow to the heart.

The other options do not reflect the primary indication for Integrilin. For instance, although stroke management is important, Integrilin is not primarily utilized for treating acute strokes. It is also not indicated as a long-term anticoagulant; rather, it is used for short-term management during acute settings. While stable angina can involve similar cardiac concerns, therapies for stable angina typically focus on long-term management rather than the urgent interventions where Integrilin is applied.